RESUMEN
CONTEXT: Intravenous aminobisphosphonates (N-BPs) can induce an acute phase reaction (APR) in up to 40% to 70% of first infusions, causing discomfort and often requiring intervention with analgesics or antipyretics. OBJECTIVE: Our aim was to explore the risk factors of APR in a large sample of patients with Paget's disease of bone (PDB) and to assess the possible preventive effects of vitamin D administration. METHODS: An observational analysis was performed in 330 patients with PDB at the time of N-BP infusion. Then, an interventional study was performed in 66 patients with active, untreated PDB to evaluate if vitamin D administration (oral cholecalciferol 50 000 IU/weekly for 8 weeks before infusion) may prevent APR. RESULTS: In a retrospective study, APR occurred in 47.6% and 18.3% of naive or previously treated patients, respectively. Its prevalence progressively increased in relation to the severity of vitamin D deficiency, reaching 80.0% in patients with 25-hydroxyvitamin D (25OHD) levels below 10 ng/mL (relative risk (RR) = 3.7; 95% confidence interval (CI) 2.8-4.7, P < .0001), even in cases previously treated with N-BPs. Moreover, APR occurred more frequently in patients who experienced a previous APR (RR = 2.8; 95% CI 1.5-5.2; P < .001) or in carriers of SQSTM1 mutation (RR = 2.3; 95% CI 1.3-4.2; P = .005). In the interventional study, vitamin D supplementation prevented APR in most cases, equivalent to a RR of 0.31 (95% CI 0.14-0.67; P < .005) with respect to prevalence rates of the observational cohort. A similar trend was observed concerning the occurrence of hypocalcemia. CONCLUSIONS: The achievement of adequate 25OHD levels is recommended before N-BP infusion in order to minimize the risk of APR or hypocalcemia in PDB.
Asunto(s)
Reacción de Fase Aguda/prevención & control , Conservadores de la Densidad Ósea/efectos adversos , Colecalciferol/administración & dosificación , Difosfonatos/efectos adversos , Osteítis Deformante/tratamiento farmacológico , Deficiencia de Vitamina D/dietoterapia , Reacción de Fase Aguda/inducido químicamente , Reacción de Fase Aguda/epidemiología , Reacción de Fase Aguda/inmunología , Administración Oral , Anciano , Anciano de 80 o más Años , Conservadores de la Densidad Ósea/administración & dosificación , Suplementos Dietéticos , Difosfonatos/administración & dosificación , Femenino , Humanos , Infusiones Intravenosas , Masculino , Persona de Mediana Edad , Osteítis Deformante/sangre , Osteítis Deformante/complicaciones , Prevalencia , Estudios Retrospectivos , Resultado del Tratamiento , Vitamina D/análogos & derivados , Vitamina D/sangre , Deficiencia de Vitamina D/sangre , Deficiencia de Vitamina D/etiología , Deficiencia de Vitamina D/inmunologíaRESUMEN
INTRODUCTION: Zoledronic acid infusion is used to treat osteoporosis but patients, especially Japanese patients, often experience acute-phase reactions (APRs). In this multicenter, randomized, open-label, parallel-group study, we examined the efficacy of the most commonly used non-steroidal anti-inflammatory drug loxoprofen in Japan in reducing the incidence rate of zoledronic acid-induced APRs and body temperature, and investigated risk/protective factors for APRs in this population. MATERIALS AND METHODS: Patients aged ≥ 60 years with primary osteoporosis (n = 368) were allocated randomly to zoledronic acid plus loxoprofen (ZOL + LOX) or zoledronic acid alone (ZOL). All patients received 5-mg zoledronic acid infusion on day 1, and patients in the ZOL + LOX group also received 120 mg and 180 mg of oral loxoprofen on days 1 and 2, respectively. Adverse events and body temperature were recorded during the 7-day observation period. RESULTS: The incidence rates of APRs were 34.4% (64/186 patients) and 47.8% (87/182 patients) in the ZOL + LOX and ZOL groups, respectively (P = 0.0109). The proportions of patients with increased body temperature (≥ 1 °C and ≥ 37.5 °C) were similar in both groups (P = 0.1186). Past bisphosphonate users had a significantly lower incidence rate of APRs than treatment-naïve patients (odds ratio 0.444, 95% confidence interval 0.285-0.692, P = 0.0003). CONCLUSIONS: Zoledronic acid-induced APRs appeared to be suppressed by loxoprofen. Known risk/protective factors, including prior osteoporosis treatment, were applicable to Japanese patients.
Asunto(s)
Reacción de Fase Aguda/inducido químicamente , Reacción de Fase Aguda/tratamiento farmacológico , Antiinflamatorios no Esteroideos/uso terapéutico , Pueblo Asiatico , Conservadores de la Densidad Ósea/uso terapéutico , Ácido Zoledrónico/efectos adversos , Reacción de Fase Aguda/epidemiología , Anciano , Temperatura Corporal , Difosfonatos/uso terapéutico , Femenino , Humanos , Incidencia , Japón , Modelos Logísticos , Masculino , Análisis Multivariante , Oportunidad Relativa , Factores de Riesgo , Resultado del Tratamiento , Ácido Zoledrónico/uso terapéuticoAsunto(s)
Reacción de Fase Aguda/epidemiología , Biomarcadores/sangre , Proteína C-Reactiva/metabolismo , Calcifediol/sangre , Enfermedades Cardiovasculares/epidemiología , Anciano , Anciano de 80 o más Años , Atención Ambulatoria , Femenino , Hospitalización , Humanos , Masculino , Persona de Mediana Edad , Atención Primaria de Salud , Estudios Retrospectivos , Factores de Riesgo , Deficiencia de Vitamina D/diagnósticoRESUMEN
OBJECTIVE: The most common adverse reaction to zoledronic acid (ZOL) infusion is the acute phase reaction (APR), characterized by transient, usually mild, flu-like symptoms. Previous treatment with oral amino-bisphosphonates (BPs) was reported as an independent protective factor for APR, and an association between APR and 25-hydroxyvitamin D (25(OH)D) levels in BP-naïve patients treated with ZOL was identified. The aims of our study were to confirm this association and to see if it was different in patients previously treated with oral BPs compared with BP-naïve patients and to investigate the role of 25(OH)D for the time of APR onset. METHODS: We included 153 consecutive patients with postmenopausal osteoporosis undergoing their first ZOL infusion. Sixty-eight had been previously treated with oral BPs. Clinical, demographic, and serologic data were recorded. RESULTS: 25(OH)D levels were significantly lower in patients experiencing APR compared to patients without APR (26.3 ± 12.7 vs. 37.0 ± 13.5 ng/mL, respectively; P<.0001). Patients with 25(OH)D <30 ng/mL had a significantly higher risk of APR (odds ratio [OR] 4.2 [95% confidence interval [CI] 2.1-8.2]) occurring in 65%. APR was significantly less frequent in patients previously treated with oral BPs than in BP-naïve subjects (33.8% [23/68] vs 52.9% [45/85], P = .018), but only a weak association remained after correction for 25(OH)D (OR 0.5, 95% CI 0.3-1.1, P = .08). CONCLUSION: Higher baseline 25(OH)D levels appear to be protective for APR post-ZOL infusion. The role of previous treatment with oral BPs as an independent protective factor for APR should be evaluated in a larger cohort. ABBREVIATIONS: APR = acute phase reaction; BPs = amino-bisphosphonates; CI = confidence interval; 25(OH)D = 25-hydroxyvitamin D; OP = osteoporosis; OR = odds ratio; PTH = parathyroid hormone; ROC = receiver operating characteristic; ZOL = zoledronic acid.
Asunto(s)
Reacción de Fase Aguda/inducido químicamente , Conservadores de la Densidad Ósea/efectos adversos , Difosfonatos/uso terapéutico , Imidazoles/efectos adversos , Osteoporosis Posmenopáusica/tratamiento farmacológico , Vitamina D/análogos & derivados , Reacción de Fase Aguda/sangre , Reacción de Fase Aguda/epidemiología , Administración Oral , Anciano , Conservadores de la Densidad Ósea/uso terapéutico , Estudios de Casos y Controles , Difosfonatos/efectos adversos , Femenino , Humanos , Infusiones Intravenosas , Persona de Mediana Edad , Oportunidad Relativa , Estudios Prospectivos , Factores Protectores , Vitamina D/sangre , Ácido ZoledrónicoRESUMEN
OBJECTIVE: It has been reported that acute-phase reactions (APR) after infusion of 5 mg zoledronic acid for the first time is common. This study surveyed the incidence and characteristics of APR in Chinese postmenopausal women receiving 5 mg zoledronic acid intravenously for osteoporosis and to evaluate the efficacy of non-steroidal anti-inflammatory drugs (NSAID) in preventing or alleviating APR following the first 5 mg zoledronic acid infusion. METHODS: A total of 2601 patients with an average age of 68.14 ± 9.89 years and a mean body mass index of 22.90 ± 3.24 kg/m2 from 62 centers in China were treated with 5 mg zoledronic acid intravenously for the first time. The incidence of fever and pain were observed in these patients, and the time of fever or pain onset and duration, and the intensity of fever and grade of pain were also recorded. The dosage, duration, and efficacy of NSAID and safety outcomes were also documented. RESULTS: At the end of the study, 18 patients are eliminated due to incomplete records of temperature. The incidence of fever was 28.65% (740/2583) within 7 days following zoledronic acid infusion; 98.34% (727/740) occurred at 1.03 ± 0.66 days after infusion and lasted 1.72 ± 0.93 days. A total of 456 (17.53%) patients had newly onset pain (312 of 1187, 26.28%) or experienced pain aggravation (144 of 1414, 10.18%), which mostly occurred within 3 days after zoledronic acid infusion. A total of 1246 (47.6%) patients had received NSAID for a median time of 2.63 ± 2.45 days. Using NSAID for at least 2 days could decrease body temperature by 0.54 ± 0.86°C, increase the percentage of pain-free patients by 6.17%, and reduce the percentage of patients with moderate to severe pain by 8.7%. CONCLUSIONS: Compared with Western populations, Chinese patients had a higher rate of fever and pain after their first zoledronic acid infusion. These symptoms were often mild to moderate in intensity and transient in duration. NSAID could effectively reduce the incidence and severity of such APR.
Asunto(s)
Reacción de Fase Aguda/inducido químicamente , Conservadores de la Densidad Ósea/efectos adversos , Difosfonatos/efectos adversos , Imidazoles/efectos adversos , Osteoporosis Posmenopáusica/tratamiento farmacológico , Reacción de Fase Aguda/epidemiología , Reacción de Fase Aguda/prevención & control , Anciano , Antiinflamatorios no Esteroideos/uso terapéutico , Conservadores de la Densidad Ósea/administración & dosificación , Conservadores de la Densidad Ósea/uso terapéutico , China/epidemiología , Difosfonatos/administración & dosificación , Difosfonatos/uso terapéutico , Femenino , Humanos , Imidazoles/administración & dosificación , Imidazoles/uso terapéutico , Incidencia , Infusiones Intravenosas , Persona de Mediana Edad , Osteoporosis Posmenopáusica/epidemiología , Dolor/inducido químicamente , Dolor/epidemiología , Dolor/prevención & control , Vigilancia de Productos Comercializados/métodos , Ácido ZoledrónicoRESUMEN
Introducción. Los estudios respecto a la asociación entre composición corporal y actividad inflamatoria en artritis reumatoide (AR) muestran resultados contradictorios. Objetivo. Realizar una revisión sistemática de la literatura sobre la asociación entre sobrepeso/obesidad y nivel de actividad inflamatoria en AR. Metodología. Enfoque FAST: búsqueda (Medline, EBSCO, biblioteca Cochrane); revisión de resúmenes, selección para lectura en texto completo y evaluación de la calidad metodológica para inclusión. Debido a la heterogeneidad en el análisis y evaluación de la actividad de la AR, realizamos metaanálisis; los resultados se presentan como síntesis cualitativa. Resultados. Se identificaron 119 artículos; 16 fueron revisados en texto completo. Se incluyeron 11 artículos (8.147 pacientes; rango n: 37-5.161) que aprobaron la evaluación de calidad metodológica. La concordancia interevaluador para la calidad metodológica (CCI: 0,93; IC 95%:0,82-0,98; p<0,001) y la decisión aceptación/rechazo (k 1,00, p>0,001) fueron excelentes. En todos los estudios la composición corporal se evaluó mediante IMC, pero hubo marcada heterogeneidad en la evaluación de la actividad inflamatoria. Se encontró asociación significativa entre actividad clínica y mayores valores de IMC en 6 estudios de mayor tamaño muestral promedio (1.274; rango: 140-5.161), mientras que en 5 con menor tamaño muestral promedio (100; rango: 37-150) no se encontró asociación entre actividad e IMC. Conclusiones. La asociación entre actividad de la AR e IMC en los estudios con tendencia a mayor potencia estadística indica que la masa grasa podría modular el estado clínico en AR. El estudio de la relación entre composición corporal y actividad inflamatoria en AR requiere de más estudios y de mayor calidad metodológica (AU)
Background. Reports regarding the association between body composition and inflammatory activity in rheumatoid arthritis (RA) have consistently yielded contradictory results. Objective. To perform a systematic review on the association between overweight/obesity and inflammatory activity in RA. Methods. FAST approach: Article search (Medline, EBSCO, Cochrane Library), followed by abstract retrieval, full text review and blinded assessment of methodological quality for final inclusion. Because of marked heterogeneity in statistical approach and RA activity assessment method, a meta-analysis could not be done. Results are presented as qualitative synthesis. Results. One hundred and nineteen reports were found, 16 of them qualified for full text review. Eleven studies (8,147 patients; n range: 37-5,161) approved the methodological quality filter and were finally included. Interobserver agreement for methodological quality score (ICC: 0.93; 95% CI: 0.82-0.98; P<.001) and inclusion/rejection decision (k 1.00, P>.001) was excellent. In all reports body composition was assessed by BMI; however a marked heterogeneity was found in the method used for RA activity assessment. A significant association between BMI and RA activity was found in 6 reports having larger mean sample size: 1,274 (range: 140-5,161). On the other hand, this association was not found in 5 studies having lower mean sample size: 100 (range: 7-150). Conclusions. The modulation of RA clinical status by body fat mass is suggested because a significant association was found between BMI and inflammatory activity in those reports with a trend toward higher statistical power. The relationship between body composition and clinical activity in RA requires be approached with further studies with higher methodological quality (AU)
Asunto(s)
Humanos , Masculino , Femenino , Composición Corporal/fisiología , Artritis/epidemiología , Artritis Reumatoide/epidemiología , Inflamación/complicaciones , Inflamación/epidemiología , Índice de Masa Corporal , Sobrepeso/complicaciones , Sobrepeso/epidemiología , Obesidad/complicaciones , Obesidad/epidemiología , Reacción de Fase Aguda/complicaciones , Reacción de Fase Aguda/epidemiología , Bibliometría , Análisis de RegresiónRESUMEN
While prenatal Fe supplementation prevents maternal Fe deficiency and anaemia, it is uncertain whether it improves infant health outcomes, at least when taken by Fe-replete women. Inflammation as well as physiological changes complicates the assessment of Fe status during pregnancy. In the present study, we measured the concentrations of serum ferritin and soluble transferrin receptors (sTfR), Hb and the acute-phase proteins C-reactive protein (CRP) and α1-antichymotrypsin (ACT) in a cross-sectional study among 738 pregnant women attending antenatal care in Guinea-Bissau, West Africa. Multiple linear regression analysis was used to identify the predictors of Fe status markers. The mean gestational age was 23 (sd 7) weeks. Serum ferritin values were lower with progressing gestation, from 27% lower during weeks 16-20 of gestation up to 59% lower after 29 weeks of gestation compared with early pregnancy. Using cut-off values for Fe deficiency as established in non-pregnant individuals, 52% of the women had sTfR levels >2·3 mg/l, while only 25% had serum ferritin levels 2·3 mg/l decreased to 47% after adjustment for elevated serum CRP and ACT levels. On the contrary, the proportion of serum ferritin < 12 µg/l increased to 33% after adjustment for ACT and CRP. The high proportion of elevated serum sTfR calls for pregnancy-specific cut-offs since increased erythropoiesis is expected in response to increased plasma volume of pregnancy. The present study further underlines the need to adjust for inflammation when serum sTfR and serum ferritin are used to assess Fe status in pregnancy.
Asunto(s)
Reacción de Fase Aguda/sangre , Reacción de Fase Aguda/epidemiología , Anemia Ferropénica/epidemiología , Biomarcadores/sangre , Hierro/sangre , Complicaciones Hematológicas del Embarazo/epidemiología , Adolescente , Adulto , Anemia Ferropénica/sangre , Proteína C-Reactiva/metabolismo , Estudios Transversales , Suplementos Dietéticos , Femenino , Ferritinas/sangre , Guinea Bissau/epidemiología , Humanos , Hierro de la Dieta/administración & dosificación , Modelos Lineales , Embarazo , Complicaciones Hematológicas del Embarazo/sangre , Receptores de Transferrina/sangre , Adulto Joven , alfa 1-Antiquimotripsina/sangreAsunto(s)
Reacción de Fase Aguda/sangre , Coagulación Sanguínea/fisiología , Catecolaminas/sangre , Cardiomiopatía de Takotsubo/sangre , Trombosis/sangre , Reacción de Fase Aguda/diagnóstico por imagen , Reacción de Fase Aguda/epidemiología , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Radiografía , Cardiomiopatía de Takotsubo/diagnóstico por imagen , Cardiomiopatía de Takotsubo/epidemiología , Trombosis/epidemiologíaRESUMEN
BACKGROUND: Intravenous bisphosphonates are widely used for treatment of postmenopausal osteoporosis. They are associated with transient influenza-like symptoms, predominantly after the first zoledronic acid (up to 32 %) or ibandronate (up to 5 %) administration. The experience in clinical practice suggests that the incidence of post-dose symptoms is higher than has been reported in clinical trials. We assessed the safety of annual infusions of zoledronic acid and 3-monthly injections of ibandronate in women with postmenopausal osteoporosis. METHODS: In this retrospective study we analysed safety data from 272 postmenopausal women treated with zoledronic acid (n = 127; mean age 68.6 ± 9.4 years) or intravenous (IV) ibandronate (n = 145; mean age 69.1 ± 9.0 years). Safety data (including occurrence of acute-phase reactions and osteonecrosis of the jaw) were gathered in phone call interviews by using a standardized questionnaire. RESULTS: The number of patients with adverse events was significantly higher in zoledronic acid as compared to ibandronate-treated patients, primarily because of a larger number of post-dose symptoms after bisphosphonate administrations (54.3 % vs. 33.1 %, p < 0.001). Except for occurrence of fever (more common after zoledronic acid infusion), other influenza-like symptoms (myalgia, arthralgia, headache) appeared in a similar proportion of patients after IV treatment (within 24-36 h). Symptoms lasted for >3 days in approximately 50 % of patients. The incidence of symptoms decreased after subsequent infusions. The rate of influenza-like symptoms was more frequent after zoledronic acid than after IV ibandronate in bisphosphonate-naïve patients but comparable in patients pretreated with oral bisphosphonates. There were no spontaneous reports of osteonecrosis of the jaw, arrhythmia or delayed fracture healing. CONCLUSION: Although IV bisphosphonates are generally safe, the occurrence of transient influenza-like symptoms after IV bisphosphonates seems to be more frequent in clinical practice than has been reported in clinical trials.
Asunto(s)
Conservadores de la Densidad Ósea/efectos adversos , Difosfonatos/efectos adversos , Imidazoles/efectos adversos , Osteoporosis Posmenopáusica/tratamiento farmacológico , Reacción de Fase Aguda/inducido químicamente , Reacción de Fase Aguda/epidemiología , Anciano , Osteonecrosis de los Maxilares Asociada a Difosfonatos/epidemiología , Osteonecrosis de los Maxilares Asociada a Difosfonatos/etiología , Conservadores de la Densidad Ósea/administración & dosificación , Conservadores de la Densidad Ósea/uso terapéutico , Difosfonatos/administración & dosificación , Difosfonatos/uso terapéutico , Esquema de Medicación , Femenino , Humanos , Ácido Ibandrónico , Imidazoles/administración & dosificación , Imidazoles/uso terapéutico , Incidencia , Infusiones Intravenosas , Inyecciones Intravenosas , Persona de Mediana Edad , Estudios Retrospectivos , Ácido ZoledrónicoRESUMEN
We determined in a prospective cohort of patients treated with vitamin K antagonists for venous thrombosis, the course of factor VIII (FVIII:C), C-reactive protein (CRP) and fibrinogen levels, to assess the influence of the acute phase reaction on FVIII:C levels. Second, we hypothesized that patients with preceding infectious symptoms might have higher levels of FVIII:C at baseline than patients without those. We included 75 patients. Blood was sampled at baseline, once during treatment (t=1) and at the end of treatment (t=2). Mean levels of FVIII:C were 207, 186 and 175IU/dL (p for trend 0.003) at baseline, t=1 and t=2 respectively. Eight-eight percent of patients had an elevated FVIII:C at baseline, 75% at t=1 and 72% at t=2 (p for trend 0.045). Mean levels of FVIII:C were not different in patients with or without preceding infectious symptoms (206 versus 205IU/dL respectively). A baseline CRP level below 62mg/L could best distinguish between patients who will keep an elevated FVIII:C and those who will drop below 150IU/dL. We conclude that FVIII:C levels are partially influenced by the acute phase reaction, especially in patients who keep a persistent elevated FVIII:C during treatment. Preceding infectious symptoms did not influence baseline FVIII:C levels.
Asunto(s)
Reacción de Fase Aguda/sangre , Reacción de Fase Aguda/epidemiología , Factor VIII/análisis , Trombosis de la Vena/sangre , Trombosis de la Vena/epidemiología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores/sangre , Comorbilidad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Países Bajos/epidemiología , Prevalencia , Estudios Prospectivos , Reproducibilidad de los Resultados , Medición de Riesgo , Factores de Riesgo , Sensibilidad y Especificidad , Adulto JovenRESUMEN
The transplantation of allogeneic or autologous haematopoietic stem cells is an established treatment for many malignant and non-malignant diseases of the bone marrow. Intensive cytoreductive regimens administered before transplantation induce prolonged and severe cytopenia of all haematopoietic lineages. Thrombocytopenia leads to an increased risk of bleeding, which may be further aggravated by consumption of plasmatic factors as a result of tumour lysis or after antibody administration. At the same time, patients after transplantation are also at increased risk of thrombotic complications. Endothelial damage induced by radio- and chemotherapy, indwelling catheters, prolonged immobilization and a high incidence of systemic infection all contribute to the frequent occurrence of thromboembolic events in this population. This review discusses the incidence and risk factors for haemorrhagic and thrombotic complications after stem cell transplantation. Special emphasis is given to complications occurring specifically in the context of transplantation such as diffuse alveolar haemorrhage, haemorrhagic cystitis, veno-occlusive disease, and transplant associated microangiopathy.
Asunto(s)
Reacción de Fase Aguda/epidemiología , Trasplante de Células Madre Hematopoyéticas/estadística & datos numéricos , Hemorragia/epidemiología , Complicaciones Posoperatorias/epidemiología , Trombosis/epidemiología , Comorbilidad , Alemania/epidemiología , Humanos , Prevalencia , Medición de Riesgo , Factores de RiesgoRESUMEN
Allogeneic and autologous hematopoietic stem cell transplantations are important therapeutic options for patients with hematologic disorders. Hemostatic complications are frequent after hematopoietic stem cell transplantation with a considerable morbidity and mortality. The incidence of bleedings and thrombosis is highest in the first few weeks after transplantation, but may also occur later. However, beyond the first year of transplantation only limited data are available. In long-term survivors the risk for premature atherosclerosis increases over time after allogeneic hematopoietic stem cell transplantation and it is higher than in the age-adjusted general population and in recipients of autologous transplantation.
Asunto(s)
Reacción de Fase Aguda/epidemiología , Trasplante de Células Madre Hematopoyéticas/estadística & datos numéricos , Hemorragia/epidemiología , Hemostasis , Complicaciones Posoperatorias/epidemiología , Trombosis/epidemiología , Comorbilidad , Alemania/epidemiología , Humanos , Prevalencia , Medición de Riesgo , Factores de RiesgoRESUMEN
There were analyzed the results of surgical treatment of 60 patients, suffering extended peritonitis (EP), in whom the content changes in the blood serum, concerning the acute phase of inflammation proteins (C-reactive protein, lactoferrin and ferritin) were studied. To all the patients a conventional basic intensi therapy was conducted postoperatively. The EP course severity was estimated using Manheim's peritoneal index (MPI): in 17 patients a I degree MPI was established, in 23 - MPI of II degree, in 20 - MPI of III degree. According to the investigation results obtained, there was established, that severity of changes of the studied indices depends on the disease course severity. The adduced indices detection makes it possible to estimate a severity of inflammatory process and efficacy of treatment conducted.
Asunto(s)
Proteínas de Fase Aguda/análisis , Reacción de Fase Aguda/sangre , Peritonitis/sangre , Reacción de Fase Aguda/epidemiología , Reacción de Fase Aguda/etiología , Estudios de Casos y Controles , Humanos , Técnicas para Inmunoenzimas , Pruebas de Fijación de Látex , Peritonitis/complicaciones , Peritonitis/epidemiología , Índice de Severidad de la EnfermedadRESUMEN
Controlled, experimental studies on the effects of acute sleep loss in humans have shown that mediators of inflammation are altered by sleep loss. Elevations in these mediators have been found to occur in healthy, rigorously screened individuals undergoing experimental vigils of more than 24h, and have also been seen in response to various durations of sleep restricted to between 25 and 50% of a normal 8h sleep amount. While these altered profiles represent small changes, such sub-clinical shifts in basal inflammatory cytokines are known to be associated with the future development of metabolic syndrome disease in healthy, asymptomatic individuals. Although the mechanism of this altered inflammatory status in humans undergoing experimental sleep loss is unknown, it is likely that autonomic activation and metabolic changes play key roles.
Asunto(s)
Inflamación/etiología , Privación de Sueño/complicaciones , Privación de Sueño/inmunología , Reacción de Fase Aguda/epidemiología , Reacción de Fase Aguda/etiología , Animales , Humanos , Inflamación/epidemiología , Resistencia a la Insulina/inmunología , Resistencia a la Insulina/fisiología , Obesidad/complicaciones , Obesidad/epidemiología , Obesidad/inmunología , Transducción de Señal/inmunología , Transducción de Señal/fisiología , Privación de Sueño/epidemiologíaRESUMEN
CONTEXT: Intravenous aminobisphosphonates often cause an acute-phase response (APR), but the precise components of this, its frequency, and the risk factors for its development have not been systematically studied. OBJECTIVE: The objective of the study was to characterize the APR and determine its frequency and the risk factors for its development. DESIGN: The study was an analysis of adverse events from a large randomized trial. SETTING: This was a multicenter international trial. PATIENTS: Patients included 7765 postmenopausal women with osteoporosis. INTERVENTION: Zoledronic acid 5 mg annually or placebo was the intervention. MAIN OUTCOME MEASURE: Adverse events occurring within 3 d of zoledronic acid infusion were measured. RESULTS: More than 30 adverse events were significantly more common in the zoledronic acid group and were regarded collectively as constituting an APR. These were clustered into five groups: fever; musculoskeletal (pain and joint swelling); gastrointestinal (abdominal pain, vomiting, diarrhea); eye inflammation; and general (including fatigue, nasopharyngitis, edema). A total of 42.4% of the zoledronic acid group had an APR after the first infusion, compared with 11.7% of the placebo group. All APR components had their peak onset within 1 d, the median duration of the APR was 3 d, and severity was rated as mild or moderate in 90%. Stepwise regression showed that APR was more common in non-Japanese Asians, younger subjects, and nonsteroidal antiinflammatory drug users and was less common in smokers, patients with diabetes, previous users of oral bisphosphonates, and Latin Americans (P < 0.05 for all). CONCLUSION: This analysis identifies new components of the APR and provides the first assessment of risk factors for it. Despite its frequency, APR rarely resulted in treatment discontinuation in this study.
Asunto(s)
Reacción de Fase Aguda/inducido químicamente , Difosfonatos/efectos adversos , Difosfonatos/uso terapéutico , Imidazoles/efectos adversos , Imidazoles/uso terapéutico , Osteoporosis Posmenopáusica/tratamiento farmacológico , Reacción de Fase Aguda/clasificación , Reacción de Fase Aguda/epidemiología , Reacción de Fase Aguda/etiología , Anciano , Anciano de 80 o más Años , Conservadores de la Densidad Ósea/efectos adversos , Conservadores de la Densidad Ósea/uso terapéutico , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/epidemiología , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/inmunología , Femenino , Humanos , Incidencia , Osteoporosis Posmenopáusica/epidemiología , Osteoporosis Posmenopáusica/inmunología , Factores de Riesgo , Índice de Severidad de la Enfermedad , Factores de Tiempo , Ácido ZoledrónicoRESUMEN
BACKGROUND & AIMS: The hypothesis of reverse epidemiology holds that some cardiovascular risk factors, such as obesity, hypercholesterolemia and hypertension, in the elderly or in some chronic diseases are not harmful but permit better survival. However, this phenomenon is controversial and the underlying reasons are poorly understood. OBJECTIVE: To search for factors simultaneously linked to reverse epidemiology and to short or long term survival. METHODS: We included 400 patients, older than 60 years, hospitalized in a general internal medicine unit; 61 died in hospital and 338 were followed up by telephone. RESULTS: Obesity, higher blood pressure and serum cholesterol, besides being related to lower mortality both in hospital and after discharge, were associated with better nutrition and functional capacity, less intense acute phase reaction and organ dysfunction, and lower incidence of high-mortality diseases such as dementia, pneumonia, sepsis or cancer. These associations may explain why obesity and other reverse epidemiology data are inversely related to mortality. Weight loss was related to mortality independently of BMI. Patients with BMI under 30 kg/m(2) who died in hospital showed more weight loss than those who survived; the lower the BMI, the greater the weight loss. In contrast, patients with BMI over 30 kg/m(2) who died in hospital gained more weight than those who survived; the higher the BMI, the greater the weight gain. CONCLUSION: In patients over 60 years of age admitted to an internal medicine ward, obesity did not show independent survival value, being displaced by other nutritional parameters, functional capacity, acute phase reaction, organ dysfunction and diseases with poor prognosis.
Asunto(s)
Hipercolesterolemia/mortalidad , Hipertensión/mortalidad , Obesidad/mortalidad , Reacción de Fase Aguda/complicaciones , Reacción de Fase Aguda/epidemiología , Reacción de Fase Aguda/prevención & control , Anciano , Anciano de 80 o más Años , Índice de Masa Corporal , Demencia/complicaciones , Demencia/epidemiología , Demencia/prevención & control , Femenino , Hospitales Universitarios , Humanos , Hipercolesterolemia/complicaciones , Hipertensión/complicaciones , Masculino , Persona de Mediana Edad , Neoplasias/complicaciones , Neoplasias/epidemiología , Neoplasias/prevención & control , Estado Nutricional , Obesidad/complicaciones , Neumonía/complicaciones , Neumonía/epidemiología , Neumonía/prevención & control , Sepsis/complicaciones , Sepsis/epidemiología , Sepsis/prevención & control , Análisis de Supervivencia , Pérdida de PesoRESUMEN
Mastitis is one of the most prevalent diseases in cattle and remains among the most costly diseases to the dairy industry. Various surveys have indicated a greater prevalence of and risk for mastitis in Holstein cows than in Jersey cows. The innate immune system comprises the immediate host defense mechanisms that respond to infection, and differences in the magnitude and rapidity of this response are known to influence susceptibility to and clearance of infectious pathogens. The reported differences in the prevalence of mastitis between Holstein and Jersey cows may suggest the occurrence of breed-dependent differences in the innate immune response to intramammary infection. The objective of the current study was to compare the acute phase and cytokine responses of Holstein and Jersey cows following intramammary infection by the bacterial pathogen Escherichia coli, a leading cause of clinical mastitis. All cows in the study were in similar stages of lactation, of the same parity, subjected to the same housing and management conditions, and experimentally infected on the same day with the same inoculum preparation. Before and after infection, the following innate immune parameters were monitored: bacterial clearance; febrile response; induction of the acute phase proteins serum amyloid A and lipopolysaccharide-binding protein; alterations in total and differential white blood cell counts; changes in milk somatic cell counts and mammary vascular permeability; and induction of the cytokines IFN-gamma, IL-1beta, IL-8, IL-12, and tumor necrosis factor-alpha. Overall innate immune responses were similar between the 2 breeds; however, temporal differences in the onset, cessation, and duration of several responses were detected. Despite these differences, intramammary clearance of E. coli was comparable between the breeds. Together, these data demonstrate a highly conserved innate immune response of Holstein and Jersey cows to E. coli intramammary infection.
Asunto(s)
Cruzamiento , Citocinas/análisis , Infecciones por Escherichia coli/veterinaria , Inmunidad Innata , Glándulas Mamarias Animales , Mastitis Bovina/inmunología , Proteínas de Fase Aguda/análisis , Proteínas de Fase Aguda/inmunología , Proteínas de Fase Aguda/metabolismo , Reacción de Fase Aguda/epidemiología , Reacción de Fase Aguda/inmunología , Reacción de Fase Aguda/veterinaria , Animales , Proteínas Portadoras/inmunología , Bovinos , Citocinas/biosíntesis , Susceptibilidad a Enfermedades/epidemiología , Susceptibilidad a Enfermedades/inmunología , Susceptibilidad a Enfermedades/veterinaria , Escherichia coli , Infecciones por Escherichia coli/epidemiología , Infecciones por Escherichia coli/inmunología , Infecciones por Escherichia coli/microbiología , Femenino , Interferón gamma/análisis , Interferón gamma/metabolismo , Interleucina-1/análisis , Interleucina-1/biosíntesis , Interleucina-12/análisis , Interleucina-12/biosíntesis , Interleucina-8/análisis , Interleucina-8/biosíntesis , Glándulas Mamarias Animales/inmunología , Glándulas Mamarias Animales/microbiología , Mastitis Bovina/epidemiología , Mastitis Bovina/metabolismo , Mastitis Bovina/microbiología , Glicoproteínas de Membrana/inmunología , Prevalencia , Factores de Riesgo , Factores de TiempoRESUMEN
RATIONALE: Physical activity is reduced in patients with chronic obstructive pulmonary disease (COPD). COPD has a systemic component that includes significant extrapulmonary effects that may contribute to its severity in individual patients. OBJECTIVES: To investigate the association of extrapulmonary effects of the disease and its comorbidities with reduced physical activity in patients with COPD. METHODS: In a cross-sectional study, 170 outpatients with COPD (GOLD [Global Initiative for Chronic Obstructive Lung Disease] stages I-IV; BODE [body mass index, airway obstruction, dyspnea, and exercise capacity] score 0-10) underwent a series of tests. Physical activity was assessed over 5 to 6 consecutive days by using a multisensor accelerometer armband that records steps per day and the physical activity level (total daily energy expenditure divided by whole-night sleeping energy expenditure). Cardiovascular status was assessed by echocardiography, vascular Doppler sonography, and levels of N-terminal pro-B-type natriuretic peptide. Mental status, metabolic/muscular status, systemic inflammation, and anemia were assessed by Beck Depression Inventory, bioelectrical impedance analysis, handgrip strength, high-sensitivity C-reactive protein/fibrinogen, and hemoglobin, respectively. MEASUREMENTS AND MAIN RESULTS: In a multivariate linear regression analysis using either steps per day or physical activity level as a dependent variable, the extrapulmonary parameters that were associated with reduced physical activity in patients with COPD independently of GOLD stages or BODE score were N-terminal pro-B-type natriuretic peptide levels, echocardiographically measured left ventricular diastolic function, and systemic inflammation. CONCLUSIONS: Higher values of systemic inflammation and left cardiac dysfunction are associated with reduced physical activity in patients with COPD.
Asunto(s)
Actividades Cotidianas , Ejercicio Físico , Enfermedad Pulmonar Obstructiva Crónica/epidemiología , Enfermedad Pulmonar Obstructiva Crónica/fisiopatología , Reacción de Fase Aguda/epidemiología , Reacción de Fase Aguda/fisiopatología , Anciano , Enfermedades Cardiovasculares/epidemiología , Enfermedades Cardiovasculares/fisiopatología , Comorbilidad , Estudios Transversales , Metabolismo Energético , Femenino , Alemania/epidemiología , Humanos , Modelos Lineales , Masculino , Persona de Mediana Edad , Análisis Multivariante , Índice de Severidad de la Enfermedad , Disfunción Ventricular Izquierda/epidemiología , Disfunción Ventricular Izquierda/fisiopatologíaRESUMEN
This study examined the ethnic difference in the association between increased serum ferritin (SF) (>300 microg/l) and acute inflammation (AI) (C-reactive protein > or = 1.0 mg/dl) between black and white males aged > or = 20 years. Using data from the third National Health and Nutrition Examination Survey (NHANES III), we determined the risk for having elevated SF in black males (n=164) and white males (n=325) with AI present as well as black males (n=1731) and white males (n=2877) with AI absent. Black subjects with AI present were 1.71 times (95% CI 1.18-2.49), and 1.87 times (95% CI 1.46-2.40) more likely to have increased SF than AI absent blacks and AI present whites, respectively. Furthermore, with AI present, every increment of C-reactive protein, white blood cell count, serum albumin, lymphocyte count and platelet count was associated with higher odds of having elevations in SF in blacks than whites. Regardless of AI status, blacks were more likely to have elevations in SF than whites, and the prevalence of elevated SF was significantly higher in blacks than whites. This finding suggested that black males may respond to inflammation with a more aggressive rise in SF compared to white males. Future research is needed to investigate the underlying mechanisms.
Asunto(s)
Reacción de Fase Aguda/sangre , Reacción de Fase Aguda/epidemiología , Ferritinas/sangre , Reacción de Fase Aguda/etnología , Reacción de Fase Aguda/etiología , Adulto , Etnicidad/estadística & datos numéricos , Humanos , Masculino , Encuestas Nutricionales , Prevalencia , Factores de Riesgo , Encuestas y Cuestionarios , Estados Unidos/epidemiologíaRESUMEN
BACKGROUND: Bisphosphonates are synthetic analogs of inorganic pyrophosphates with high avidity for bone, where they bind to hydroxyapatite crystals. Bisphosphonates are effective in decreasing bone resorption, the incidence of skeletal-related events, and pain from bone metastases. These agents have recently become incorporated into the treatment regimen of patients with osteolytic and osteoblastic metastatic bone disease. Although relatively well tolerated, the initial dose(s) of intravenous aminobisphosphonates can be associated with an acute phase response, a nonspecific physiologic reaction associated with increased levels of inflammatory cytokines, fever, and flu like symptoms including fatigue, nausea, and myalgia. OBJECTIVE: The purpose of this article is to provide an updated review of the literature in this field. DATA SOURCE: A search of PubMed was performed using the key terms bisphosphonate, acute phase response, and cancer, and limited to publications in English. The published literature on acute phase response with bisphosphonate therapy was reviewed. RESULTS AND CONCLUSIONS: Approximately 40% of patients receiving aminobisphosphonates experience an acute phase response, which generally occurs only on first exposure to the drug and typically last <72 h. Not all bisphosphonates induce acute phase responses to the same extent. This article reviews acute phase response in patients with metastatic bone disease treated with aminobisphosphonates.